{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:41:44Z","timestamp":1789749704344,"version":"4.0.1"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2508500"],"award-info":[{"award-number":["2023YFC2508500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272951"],"award-info":[{"award-number":["82272951"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272953"],"award-info":[{"award-number":["82272953"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.canlet.2025.217980","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T23:32:53Z","timestamp":1754955173000},"page":"217980","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Watershed year of cell and gene therapy (CGT): A review of 2024 CGT approvals"],"prefix":"10.1016","volume":"632","author":[{"given":"Aiwen","family":"Jian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3945-2536","authenticated-orcid":false,"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.canlet.2025.217980_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/jamasurg.2024.4893","article-title":"Bioengineered human arteries for the repair of vascular injuries","volume":"160","author":"Moore","year":"2025","journal-title":"JAMA Surg."},{"issue":"4","key":"10.1016\/j.canlet.2025.217980_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"7","key":"10.1016\/j.canlet.2025.217980_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: state of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci. Adv."},{"issue":"7","key":"10.1016\/j.canlet.2025.217980_bib4","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.tibtech.2023.02.003","article-title":"Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy","volume":"41","author":"Xue","year":"2023","journal-title":"Trends Biotechnol."},{"issue":"10","key":"10.1016\/j.canlet.2025.217980_bib5","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.tibtech.2023.04.002","article-title":"Challenges in scaling up AAV-based gene therapy manufacturing","volume":"41","author":"Jiang","year":"2023","journal-title":"Trends Biotechnol."},{"issue":"8","key":"10.1016\/j.canlet.2025.217980_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3721","article-title":"Gene therapy clinical trials worldwide to 2023-an update","volume":"26","author":"Ginn","year":"2024","journal-title":"J. Gene Med."},{"issue":"7949","key":"10.1016\/j.canlet.2025.217980_bib8","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"issue":"1\u20132","key":"10.1016\/j.canlet.2025.217980_bib9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11010-020-03834-3","article-title":"Gene therapy: a double-edged sword with great powers","volume":"474","author":"Tang","year":"2020","journal-title":"Mol. Cell. Biochem."},{"issue":"10","key":"10.1016\/j.canlet.2025.217980_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22105233","article-title":"Ex vivo mesenchymal stem cell therapy to regenerate machine perfused organs","volume":"22","author":"Bogensperger","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.canlet.2025.217980_bib11","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","article-title":"Direct in vivo CAR T cell engineering","volume":"45","author":"Short","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.canlet.2025.217980_bib12","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol. Ther. : J. Amer. Soc. Gene Ther."},{"issue":"1","key":"10.1016\/j.canlet.2025.217980_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1938","article-title":"CRISPR\/Cas gene editing and delivery systems for cancer therapy","volume":"16","author":"Li","year":"2024","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"issue":"6372","key":"10.1016\/j.canlet.2025.217980_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan4672","article-title":"Gene therapy comes of age","volume":"359","author":"Dunbar","year":"2018","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.canlet.2025.217980_bib15","series-title":"Gene Therapy Market Size, Share & Trends Analysis Report by Indication (Acute Lymphoblastic Leukemia, Large B-cell Lymphoma)","first-page":"2024","author":"Research","year":"2024"},{"key":"10.1016\/j.canlet.2025.217980_bib16","year":"2024","journal-title":"Cell and Gene Therapy Sector Report"},{"issue":"1","key":"10.1016\/j.canlet.2025.217980_bib17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41587-024-02520-9","article-title":"As new cell and gene therapies emerge from academia, we must RISE to the opportunity","volume":"43","author":"Uma","year":"2025","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.canlet.2025.217980_bib19","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3343\/alm.2023.0382","article-title":"Manufacturing cell and gene therapies: challenges in clinical translation","volume":"44","author":"Lee","year":"2024","journal-title":"Ann. lab. med."},{"issue":"7","key":"10.1016\/j.canlet.2025.217980_bib20","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2025.217980_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/B978-0-323-90120-8.00013-7","article-title":"Clinical trial designs and endpoints","volume":"205","author":"Zeissler","year":"2024","journal-title":"Handb. Clin. Neurol."},{"issue":"6","key":"10.1016\/j.canlet.2025.217980_bib22","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/s41375-025-02585-8","article-title":"Current landscape of vector safety and genotoxicity after hematopoietic stem or immune cell gene therapy","volume":"39","author":"Ottaviano","year":"2025","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.canlet.2025.217980_bib23","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41417-019-0157-z","article-title":"Autologous CAR T-cell therapies supply chain: challenges and opportunities?","volume":"27","author":"Papathanasiou","year":"2020","journal-title":"Cancer Gene Ther."},{"issue":"12","key":"10.1016\/j.canlet.2025.217980_bib24","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1016\/j.ymthe.2023.11.001","article-title":"The state of cell and gene therapy in 2023","volume":"31","author":"Chancellor","year":"2023","journal-title":"Mol. Ther. : J. Amer. Soc. Gene Ther."},{"key":"10.1016\/j.canlet.2025.217980_bib25","unstructured":"FDA Announces Comprehensive Regenerative Medicine Policy Framework [press release]."},{"issue":"3","key":"10.1016\/j.canlet.2025.217980_bib26","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1177\/2168479018779373","article-title":"Expediting drug development: fda's new regenerative medicine advanced therapy designation","volume":"53","author":"Vaggelas","year":"2019","journal-title":"Therap. innov. & regul. sci."},{"key":"10.1016\/j.canlet.2025.217980_bib27","series-title":"FDA Announces Plan to Phase out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs","year":"2025"},{"key":"10.1016\/j.canlet.2025.217980_bib28","series-title":"Opinions of the state council on reform of the evaluation and approval system of drugs and medical devices. [in Chinese] [press release]","year":"2015"},{"key":"10.1016\/j.canlet.2025.217980_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1151784","article-title":"Review time of oncology drugs and its underlying factors: an exploration in China","volume":"14","author":"Zhu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2025.217980_bib30","series-title":"European Medicines Agency Pre-authorisation Procedural Advice for Users of the Centralised Procedure","year":"2025"},{"key":"10.1016\/j.canlet.2025.217980_bib31","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/164_2023_648","article-title":"Regulatory aspects for approval of advanced therapy medicinal products in the EU","volume":"284","author":"F\u00fcrst-Ladani","year":"2024","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.canlet.2025.217980_bib32","series-title":"Procedural Advice on the Accelerated Assessment of Marketing Authorisation Applications Pursuant to Article 44 (3) of Regulation (EU) No 2019\/6","year":"2024"},{"key":"10.1016\/j.canlet.2025.217980_bib33","unstructured":"Reviews and related services on regenerative medical products [Available from: https:\/\/www.pmda.go.jp\/english\/review-services\/reviews\/0003.html."},{"key":"10.1016\/j.canlet.2025.217980_bib34","unstructured":"Regulatory Update from MHLW\/PMDA [press release]."},{"key":"10.1016\/j.canlet.2025.217980_bib35","series-title":"Consideration Point of Post-approval Change","year":"2016"},{"key":"10.1016\/j.canlet.2025.217980_bib36","series-title":"Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review","year":"2023"},{"issue":"5","key":"10.1016\/j.canlet.2025.217980_bib37","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s10637-021-01117-2","article-title":"The drug lag issue: a 20-year review of China","volume":"39","author":"Li","year":"2021","journal-title":"Invest. N. Drugs"},{"issue":"11","key":"10.1016\/j.canlet.2025.217980_bib38","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nrd.2016.200","article-title":"Innovative drug availability in China","volume":"15","author":"Shao","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.canlet.2025.217980_bib39","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s41256-024-00396-5","article-title":"Regulatory efforts to address the access gap for foreign new drugs in China: the priority review program and related policies","volume":"10","author":"Zhu","year":"2025","journal-title":"Glob. Health Res. Pol."},{"key":"10.1016\/j.canlet.2025.217980_bib40","series-title":"Sect. Decree of the State Administration for Market Regulation No. 27","year":"2020"},{"key":"10.1016\/j.canlet.2025.217980_bib41","unstructured":"Benefit-Risk Methodology."},{"key":"10.1016\/j.canlet.2025.217980_bib43","author":"Commission"},{"key":"10.1016\/j.canlet.2025.217980_bib45","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.944927","article-title":"Editorial: first regulatory approval for adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TILs) - lifileucel (Amtagvi)","volume":"30","author":"Parums","year":"2024","journal-title":"Med. Sci. Monit. : Int. med. j. exp. clin. res."},{"issue":"3","key":"10.1016\/j.canlet.2025.217980_bib46","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40291-025-00771-z","article-title":"Obecabtagene autoleucel: first approval","volume":"29","author":"Lee","year":"2025","journal-title":"Mol. Diagn. Ther."},{"issue":"4","key":"10.1016\/j.canlet.2025.217980_bib47","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jcyt.2025.01.005","article-title":"ISCT MSC committee statement on the US FDA approval of allogenic bone-marrow mesenchymal stromal cells","volume":"27","author":"Blanc","year":"2025","journal-title":"Cytotherapy"},{"issue":"24","key":"10.1016\/j.canlet.2025.217980_bib48","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J. Clin. Oncol. : off. j. Amer. Soc. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217980_bib49","series-title":"Delivery Techniques for Enhancing CAR T Cell Therapy Against Solid Tumors","volume":"vol. 31","author":"Fu","year":"2021"},{"issue":"1","key":"10.1016\/j.canlet.2025.217980_bib50","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41378-023-00616-x","article-title":"Microphysiological systems for solid tumor immunotherapy: opportunities and challenges","volume":"9","author":"Abizanda-Campo","year":"2023","journal-title":"Microsyst. & Nanoeng."},{"issue":"3","key":"10.1016\/j.canlet.2025.217980_bib51","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40291-025-00771-z","article-title":"Obecabtagene autoleucel: first approval","volume":"29","author":"Lee","year":"2025","journal-title":"Mol. Diagn. Ther."},{"issue":"1","key":"10.1016\/j.canlet.2025.217980_bib52","doi-asserted-by":"crossref","first-page":"183","DOI":"10.20517\/evcna.2025.02","article-title":"A milestone for the therapeutic EV field: FDA approves Ryoncil, an allogeneic bone marrow-derived mesenchymal stromal cell therapy","volume":"6","author":"Giebel","year":"2025","journal-title":"Extracell. ves. circulat. nucl. acids"},{"issue":"23","key":"10.1016\/j.canlet.2025.217980_bib53","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-Cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.canlet.2025.217980_bib54","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","article-title":"The journey of CAR-T therapy in hematological malignancies","volume":"21","author":"Lu","year":"2022","journal-title":"Mol. Cancer"},{"issue":"16_suppl","key":"10.1016\/j.canlet.2025.217980_bib55","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1200\/JCO.2023.41.16_suppl.7000","article-title":"Safety and efficacy of obecabtagene autoleucel (Obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed\/refractory adult B-cell acute lymphoblastic leukemia (r\/r B-ALL): top line results of the pivotal FELIX study","volume":"41","author":"Roddie","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217980_bib56","series-title":"FDA Approves New CAR-T Competitor to Gilead's Tecartus","author":"Gardner","year":"2024"},{"issue":"14","key":"10.1016\/j.canlet.2025.217980_bib57","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol. : off. j. Amer. Soc. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.canlet.2025.217980_bib58","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1007\/s00018-019-03125-1","article-title":"Biological functions of mesenchymal stem cells and clinical implications","volume":"76","author":"Naji","year":"2019","journal-title":"Cell. Mol. Life Sci. : CMLS"},{"key":"10.1016\/j.canlet.2025.217980_bib59","article-title":"Treatment of steroid-refractory acute graft-versus-host disease using commercial mesenchymal stem","volume":"12","author":"Murata","year":"2021","journal-title":"Cell Products"},{"key":"10.1016\/j.canlet.2025.217980_bib60","first-page":"139","volume":"1420","author":"Torrents","year":"2023"},{"key":"10.1016\/j.canlet.2025.217980_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.648472","article-title":"Acceleration of translational mesenchymal stromal cell therapy through consistent quality GMP manufacturing","volume":"9","author":"Jayaraman","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.canlet.2025.217980_bib62","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1038\/s41467-022-30896-2","article-title":"Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing","volume":"13","author":"Jo","year":"2022","journal-title":"Nat. Commun."},{"issue":"20","key":"10.1016\/j.canlet.2025.217980_bib63","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2427216122","article-title":"Quadruple adenine base-edited allogeneic CAR T cells outperform CRISPR\/Cas9 nuclease-engineered T cells","volume":"122","author":"Engel","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"6","key":"10.1016\/j.canlet.2025.217980_bib64","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-Positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.canlet.2025.217980_bib65","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell. Mol. Immunol."},{"issue":"3","key":"10.1016\/j.canlet.2025.217980_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030648","article-title":"Treatment with Anti-HER2 chimeric antigen receptor tumor-infiltrating lymphocytes (CAR-TILs) is safe and associated with antitumor efficacy in mice and companion dogs","volume":"15","author":"Forsberg","year":"2023","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.canlet.2025.217980_bib67","doi-asserted-by":"crossref","first-page":"6376","DOI":"10.1097\/MS9.0000000000002580","article-title":"'Lenmeldy (OTL-200) in MLD: fda's validation of advanced therapy'","volume":"86","author":"Qureshi","year":"2024","journal-title":"Ann. med. surg. (2012)"},{"issue":"5","key":"10.1016\/j.canlet.2025.217980_bib68","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa0805817","article-title":"Gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"360","author":"Aiuti","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"5577","key":"10.1016\/j.canlet.2025.217980_bib69","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1126\/science.1070104","article-title":"Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning","volume":"296","author":"Aiuti","year":"2002","journal-title":"Science (New York, NY)"},{"issue":"20","key":"10.1016\/j.canlet.2025.217980_bib70","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1003548","article-title":"Stem-cell gene therapy for the Wiskott-Aldrich syndrome","volume":"363","author":"Boztug","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"7313","key":"10.1016\/j.canlet.2025.217980_bib71","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature09328","article-title":"Transfusion independence and HMGA2 activation after gene therapy of human \u03b2-thalassaemia","volume":"467","author":"Cavazzana-Calvo","year":"2010","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.canlet.2025.217980_bib72","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene therapy in a patient with sickle cell disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.canlet.2025.217980_bib73","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217980_bib74","article-title":"Phase 1 dose escalation of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate (ADC)","volume":"42","author":"Ding-Wei","year":"2024","journal-title":"JCO"},{"issue":"10435","key":"10.1016\/j.canlet.2025.217980_bib75","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D'Angelo","year":"2024","journal-title":"Lancet (London, England)"},{"issue":"12","key":"10.1016\/j.canlet.2025.217980_bib76","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2302982","article-title":"Gene therapy with fidanacogene elaparvovec in adults with hemophilia B","volume":"391","author":"Cuker","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.canlet.2025.217980_bib77","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/jama.2024.28666","article-title":"Eladocagene exuparvovec for aromatic L-Amino acid decarboxylase deficiency","volume":"333","author":"Golikeri","year":"2025","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.canlet.2025.217980_bib78","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/jimd.12649","article-title":"Gene therapy for aromatic L-amino acid decarboxylase deficiency: requirements for safe application and knowledge-generating follow-up","volume":"47","author":"Roubertie","year":"2024","journal-title":"J. Inherit. Metab. Dis."},{"issue":"2","key":"10.1016\/j.canlet.2025.217980_bib79","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clinthera.2024.12.008","article-title":"Kebilidi (eladocagene exuparvovec-tneq)","volume":"47","author":"Beninger","year":"2025","journal-title":"Clin Ther"},{"key":"10.1016\/j.canlet.2025.217980_bib80","first-page":"71","volume":"vol. 6","author":"Zhang","year":"2022"},{"key":"10.1016\/j.canlet.2025.217980_bib81","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2023-173427","article-title":"Efficacy outcomes and characteristics of patients with multiple myeloma (MM) who achieved sustained minimal residual disease negativity after treatment with equecabtagene autoleucel (Eque-cel, CT103A) in Fumanba-1","volume":"142","author":"Li","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.canlet.2025.217980_bib83","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1182\/blood-2023-184373","article-title":"Three-year Follow-up on efficacy and safety results from phase 1 lummicar study 1 of zevorcabtagene autoleucel in Chinese patients with relapsed or refractory multiple myeloma","volume":"142","author":"Fu","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.canlet.2025.217980_bib84","article-title":"Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting","volume":"13","author":"Alsdorf","year":"2024","journal-title":"J. comp. effect. res."},{"key":"10.1016\/j.canlet.2025.217980_bib85","article-title":"Bridging the new drug access gap between China and the United States and its related policies","volume":"14","author":"Zhu","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.canlet.2025.217980_bib86","first-page":"1099","article-title":"Trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022"},{"key":"10.1016\/j.canlet.2025.217980_bib87","series-title":"FDA Approves Treatment of Amyotrophic Lateral Sclerosis Associated with a Mutation in the SOD1 Gene","year":"2023"},{"issue":"12","key":"10.1016\/j.canlet.2025.217980_bib88","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"Pt A","key":"10.1016\/j.canlet.2025.217980_bib89","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.brainres.2018.02.035","article-title":"The epidemiology and genetics of Amyotrophic lateral sclerosis in China","volume":"1693","author":"Liu","year":"2018","journal-title":"Brain Res."},{"key":"10.1016\/j.canlet.2025.217980_bib90","series-title":"CAR-T Therapy Global Market Report 2024","author":"Company","year":"2024"},{"issue":"8","key":"10.1016\/j.canlet.2025.217980_bib91","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13217","article-title":"Development and regulation of stem cell-based therapies in China","volume":"55","author":"Gao","year":"2022","journal-title":"Cell Prolif."},{"issue":"5","key":"10.1016\/j.canlet.2025.217980_bib92","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.canlet.2025.217980_bib93","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.canlet.2025.217980_bib94","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nrm.2016.8","article-title":"A decade of transcription factor-mediated reprogramming to pluripotency","volume":"17","author":"Takahashi","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"23","key":"10.1016\/j.canlet.2025.217980_bib95","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11237030","article-title":"Clinical trials of stem cell therapy in Japan: the decade of progress under the national program","volume":"11","author":"Enosawa","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.canlet.2025.217980_bib96","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-025-01143-7","article-title":"Japan's big bet on stem-cell therapies might soon pay off with medical breakthroughs","volume":"640","author":"Mallapaty","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.217980_bib97","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-3-031-34567-8_9","article-title":"Regulatory aspects of cell and gene therapy products: the Japanese perspective","volume":"1430","author":"Maruyama","year":"2023","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.canlet.2025.217980_bib98","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.724380","article-title":"Treatment of steroid-refractory acute graft-versus-host disease using commercial mesenchymal stem cell products","volume":"12","author":"Murata","year":"2021","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.canlet.2025.217980_bib99","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/14737175.2019.1618710","article-title":"Neurodegenerative disease treatments by direct TNF reduction, SB623 cells, maraviroc and irisin and MCC950, from an inflammatory perspective - a commentary","volume":"19","author":"Clark","year":"2019","journal-title":"Expert Rev. Neurother."},{"issue":"7","key":"10.1016\/j.canlet.2025.217980_bib100","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209797","article-title":"Mesenchymal stromal cell implants for chronic motor deficits after traumatic brain injury: post hoc analysis of a randomized trial","volume":"103","author":"Okonkwo","year":"2024","journal-title":"Neurology"},{"issue":"8064","key":"10.1016\/j.canlet.2025.217980_bib101","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41586-025-08700-0","article-title":"Phase I\/II trial of iPS-cell-derived dopaminergic cells for Parkinson's disease","volume":"641","author":"Sawamoto","year":"2025","journal-title":"Nature"},{"issue":"10466","key":"10.1016\/j.canlet.2025.217980_bib102","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(24)01764-1","article-title":"Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: a single-arm, open-label, first-in-human interventional study in Japan","volume":"404","author":"Soma","year":"2024","journal-title":"Lancet (London, England)"},{"issue":"4","key":"10.1016\/j.canlet.2025.217980_bib103","article-title":"Transplant of induced pluripotent stem cell\u2013derived retinal pigment epithelium strips for macular degeneration and retinitis pigmentosa","volume":"5","author":"Sakai","year":"2025"},{"issue":"1","key":"10.1016\/j.canlet.2025.217980_bib104","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s43856-024-00617-5","article-title":"Graft survival of major histocompatibility complex deficient stem cell-derived retinal cells","volume":"4","author":"Ishida","year":"2024","journal-title":"Commun. Med."},{"key":"10.1016\/j.canlet.2025.217980_bib105","article-title":"ATMP development and pre-GMP environment in academia: a safety net for early cell and gene therapy development and manufacturing","volume":"16","author":"Silva","year":"2022","journal-title":"Immuno-oncol. technol."},{"issue":"3","key":"10.1016\/j.canlet.2025.217980_bib106","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1017\/S0266462316000180","article-title":"Health technology assessments reporting cost-effectiveness of transcatheter aortic valve implantation","volume":"32","author":"Kularatna","year":"2016","journal-title":"Int. J. Technol. Assess. Health Care"},{"issue":"7","key":"10.1016\/j.canlet.2025.217980_bib107","first-page":"635","article-title":"Health technology assessments in radiology in Germany: lack of demand, lack of supply","volume":"191","author":"Winkelmann","year":"2019","journal-title":"R\u00f6fo : Fortschritte dem Geb. Rontgenstrahlen Nukl."},{"issue":"6","key":"10.1016\/j.canlet.2025.217980_bib108","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41422-022-00627-9","article-title":"Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response","volume":"32","author":"He","year":"2022","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.canlet.2025.217980_bib109","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12943-023-01844-5","article-title":"The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells","volume":"22","author":"Li","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2025.217980_bib110","article-title":"1028P A phase I study of personalized KSX01-TCRT therapy for advanced solid tumor and its mechanisms","volume":"35","author":"Wang","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217980_bib111","volume":"vol. 35","author":"Wang","year":"2024"},{"issue":"1","key":"10.1016\/j.canlet.2025.217980_bib112","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13059-018-1459-4","article-title":"DeepCRISPR: optimized CRISPR guide RNA design by deep learning","volume":"19","author":"Chuai","year":"2018","journal-title":"Genome Biol."},{"issue":"7","key":"10.1016\/j.canlet.2025.217980_bib113","first-page":"478","article-title":"Massively parallel CRISPR off-target detection enables rapid off-target prediction model building","volume":"4","author":"Tian","year":"2023","journal-title":"Med (New York, NY)"},{"issue":"8071","key":"10.1016\/j.canlet.2025.217980_bib114","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41586-025-09021-y","article-title":"Custom CRISPR-Cas9 PAM variants via scalable engineering and machine learning","volume":"643","author":"Silverstein","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.217980_bib115","volume":"vol. 35","author":"Li","year":"2024"},{"issue":"1","key":"10.1016\/j.canlet.2025.217980_bib116","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12916-021-02006-4","article-title":"Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors","volume":"19","author":"Wang","year":"2021","journal-title":"BMC Med."},{"issue":"9","key":"10.1016\/j.canlet.2025.217980_bib117","doi-asserted-by":"crossref","first-page":"8579","DOI":"10.1021\/acsnano.4c14102","article-title":"Reprogramming the tolerogenic immune response against pancreatic cancer metastases by lipid nanoparticles delivering a STING agonist plus mutant KRAS mRNA","volume":"19","author":"Xu","year":"2025","journal-title":"ACS Nano"},{"issue":"12","key":"10.1016\/j.canlet.2025.217980_bib118","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525005506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525005506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:35:18Z","timestamp":1772804118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525005506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":113,"alternative-id":["S0304383525005506"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217980","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Watershed year of cell and gene therapy (CGT): A review of 2024 CGT approvals","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217980","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"217980"}}